Company intelligence / Profile preview

Celleron Therapeutics

Oxford, England, United Kingdomingenox.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Celleron has completed a Phase 1b CAROSELL clinical study evaluating the safety of a novel combination therapy for colorectal cancer. One patient from a Phase I trial continues to benefit from continuous zabadinostat therapy for over 2 years as of April 2022. A global Phase III clinical trial of zabadinostat as MSS CRC combination therapy with an immune check-point inhibitor was planned to start in 2022.

Therapeutic areas: Oncology
Modalities: Small moleculesPrecision medicine drugsCancer vaccines
Industry: Biotech

Drug pipeline

1 asset

leptazumab

Unknown

Partnerships

Astra ZenecaNuance (China partner)Roche (licensed emactuzumab to SynOx Therapeutics)

Beyond the preview

Go deeper on Celleron Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Celleron Therapeutics.

Explore the full profile